Core Viewpoint - BioAge Labs, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its initial public offering and subsequent discontinuation of a key product trial, which led to a significant drop in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased BioAge stock linked to its IPO on September 26, 2024 [2]. - The complaint highlights that BioAge announced the discontinuation of the STRIDES Phase 2 trial for azelaprag on December 6, 2024, due to safety concerns, which was unexpected given the positive outlook presented during the IPO [3]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until March 10, 2025, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [5].
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for Investors - Contact Levi & Korsinsky